Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Context Therapeutics to post earnings of ($0.09) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 12:00 AM ET.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). On average, analysts expect Context Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX opened at $1.09 on Monday. The stock has a market capitalization of $97.77 million, a P/E ratio of -3.03 and a beta of 1.94. The stock’s fifty day moving average is $1.04 and its 200 day moving average is $0.84. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.33.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, October 8th. HC Wainwright reduced their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Cantor Fitzgerald began coverage on shares of Context Therapeutics in a research note on Thursday, October 2nd. They issued an “overweight” rating on the stock. Guggenheim started coverage on Context Therapeutics in a research note on Thursday, September 18th. They set a “buy” rating and a $5.00 target price for the company. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Context Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $5.20.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.